Today's Date: April 24, 2024
Voices for Humanity Bears Witness to Panama's Moral Resurgence With Giselle Lima   •   The Village at Willow Crossings Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Th   •   Arcosa Publishes 2023 Sustainability Report   •   Ouro Teams Up with Texas One Fund with Multi-Year NIL X World Wallet Financial Empowerment Program for University of Texas Stude   •   Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada   •   Motlow State Community College Expands Accessibility With the Addition of YuJa Panorama Digital Accessibility Platform to Its Ed   •   QuantumScape Reports First Quarter 2024 Business and Financial Results   •   Orion S.A. Earns Platinum Sustainability Rating by EcoVadis   •   ESS Inc. Schedules First Quarter 2024 Financial Results Conference Call   •   White House Correspondents’ Association Dinner to Welcome Hooman Shahidi, Co-founder and CEO of EVPassport, the Rapidly Gr   •   Bay Square at Yarmouth Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai   •   Leading Industry Publication: Black & Veatch Remains Among Global Critical Infrastructure Leaders as Sustainability, Decarbo   •   ACTS LAW Addresses Federal Correctional Institution in Dublin Controversy   •   Wounded Warrior Project, White House Celebrate and Honor Warriors at Annual Soldier Ride   •   ERVIN COHEN & JESSUP PARTNER RECOGNIZED AS TOP LAWYER IN LOS ANGELES   •   Benchmark Senior Living at Hamden Assisted Living Community Named One of the Country's Best by U.S. News & World Report   •   PONIX AWARDED $5 MILLION USDA GRANT TO BREAK "GROUND" ON CLIMATE-SMART AGRICULTURE IN GEORGIA   •   The Birches at Concord Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai   •   WM Announces First Quarter 2024 Earnings   •   Santiago, Chile Will Host the 2027 Special Olympics World Games
Bookmark and Share

IceCure Medical Continues Expansion in Asia; Receives Largest Purchase Order for ProSense™ Cryoablation System

IceCure Medical Continues Expansion in Asia; Receives Largest Purchase Order for ProSense™ Cryoablation System

Healthcare Institutions Continue to Adopt Minimally Invasive Oncology Solutions to Address Growing Demand and Provide Clinical and Economic Benefits

PR Newswire

CAESAREA, Israel, April 1, 2020 /PRNewswire/ -- IceCure Medical Ltd (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women's health and Interventional oncology markets, announced today that it has received its largest purchase order (PO) for ProSense™ system from Bumrungrad International Hospital, a leading hospital based in Thailand. The order, which includes systems and probes is expected to be delivered and installed by the end of the second quarter. If travel restrictions continue due to the ongoing COVID-19 pandemic, the IceCure team has developed a strategy to deliver the system and provide remote support, installation and training to enable rapid access of its safe and effective, non-surgical cryoablation treatment to patients in Thailand.

"This is a significant achievement for IceCure and it demonstrates our continued efforts to expand our presence in key markets, such as Asia, where there is a great need for advanced solutions to treat cancer," commented Eyal Shamir, Chief Executive Officer. "During these unsettling times, global healthcare institutions are continuing to evaluate oncology solutions, and the benefits of our minimally invasive ProSense™ system eliminates the need to have the patient in an operating room (OR) environment. This is a critical and distinct advantage during normal times, but it is especially important now as the COVID-19 pandemic primarily targets those with underlying health conditions and weakened immune systems, such as those with cancer. Bumrungrad's decision, and that of others that currently evaluating ProSense™, highlights a patient-first approach and ensuring these patients are cared for in safer environments."

"IceCure's innovative minimally-invasive ProSense™ cryoablation system is consistent with our strategy to adopt cutting-edge, world-class technologies to advance patient care," said Jeremy Ford, Laboratory Research & Technology Director from Bumrungrad International Hospital. "By reducing operating room procedures, the ProSense™ system brings significant benefits in enabling a safe and effective alternative treatment for our oncology patients."

Bumrungrad International Hospital has been a global pioneer in providing world-class healthcare services and international patient support for nearly four decades. Located in the heart of Bangkok, Thailand, it is an internationally accredited, multi-specialty hospital and one of the largest private hospitals in Southeast Asia, caring for over 1.1 million patients from more than 190 countries annually.

The Company is in discussion with Terumo, one of the world's leading medical device manufacturers, its exclusive distribution partner in Japan and Singapore, to also include Thailand and help accelerate the commercialization and utilization of ProSense™ cryoablation system throughout the country.

The Company's ProSense™ system is an effective liquid nitrogen (LN2) cryoablation solution, capable of destroying tumors safely, quickly and painlessly, without the need for surgery. Guided by CT or ultrasound, the probe is inserted into the tumor and liquid nitrogen generates sub-zero temperatures to turn the tumor into an ice ball. A freeze-thaw-freeze cycle destroys the targeted tissue immediately and leaves adjacent healthy tissue undamaged. The necrotic debris is eventually absorbed by the body.

About IceCure Medical 

Founded in 2006, IceCure Medical (TASE: ICCM) is an Israeli medical device company that develops and markets an advanced liquid-nitrogen-based cryoablation therapy for women's health and the interventional oncology market, with the primary focus areas being breast, kidney and lung cancer. Its technology is a safe, effective, non-invasive alternative to surgical tumor removal that is easily performed in a short procedure. The system has US FDA 510k and CE Mark clearance and is sold worldwide. The company has a wholly-owned subsidiary in the United States, IceCure Medical Inc., with offices in New Jersey. To learn more, please visit: www.icecure-medical.com.

Cision View original content:http://www.prnewswire.com/news-releases/icecure-medical-continues-expansion-in-asia-receives-largest-purchase-order-for-prosense-cryoablation-system-301033253.html

SOURCE IceCure Medical



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News